IPO Central

Windlas Biotech IPO description – Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. In FY 2020, the company’s market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry. In addition to providing services and products in the CDMO market, the company also sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been on launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible, which was 68.5% of its total product portfolio in FY2021. Windlas Biotech operates three distinct strategic business verticals (SBVs): (i) CDMO Services and Products; (ii) Domestic Trade Generics and over-the-counter (OTC) Brands; and (iii) Exports.

Promoters of Windlas Biotech – Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass and AKW WBL Family Private Trust

IPO Opening Date: 4 August 2021
IPO Closing Date: 6 August 2021
Finalisation of Basis of Allotment: 11 August 2021
Initiation of refunds: 12 August 2021
Transfer of shares to demat accounts: 13 August 2021
Listing Date: 16 August 2021
Opening Price on NSE: INR437 per share (down 5% from IPO price)
Closing Price on NSE: INR406 per share (down 11.74% from IPO price)